ArticleExperimental & molecular medicine2022
Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis.
Article in Experimental & molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Mechanistic role of quercetin as inhibitor for adenosine deaminase enzyme in rheumatoid arthritis: systematic review.Cellular & molecular biology letters · 2024Pooled it
- Metabolic challenges in rheumatoid arthritis: a translational overview from pathogenesis to patient care.Acta diabetologica · 2026Review
- Article
- Article
- Coix Seed Oil Ameliorates Rheumatoid Arthritis by Modulating Inflammation-Associated Metabolic Pathways.Current issues in molecular biology · 2026Article
- Formononetin and Rhein from Bitong Mixture Alleviate Rheumatoid Arthritis-Related Inflammation: An Integrated WGCNA, Machine Learning and In Vitro Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Association between lipid accumulation product and visceral adiposity index and rheumatoid arthritis: NHANES 1999-2018.Lipids in health and disease · 2026Article
- Therapeutic Effect and Underlying Mechanism of Blue Mussel (Nutrients · 2026Article
- Comorbidity risk characteristics of rheumatoid arthritis in the context of depression-associated lipid metabolism.Frontiers in immunology · 2026Article
- Maresin-1 and maresin-2 as synovial fluid biomarkers in psoriatic, rheumatoid, and osteoarthritis.Frontiers in medicine · 2026Article
- Integrated metabolomics and machine learning identify predictive biomarkers via SHAP analysis for sintilimab-induced rash in lung cancer patients.Frontiers in pharmacology · 2026Article
- Untargeted metabolomics reveals immune-metabolic signatures in established cases of rheumatoid arthritis.Frontiers in molecular biosciences · 2026Article
- Fatty Acid Metabolic Reprogramming in Rheumatoid Arthritis: Integrating Inflammation, Resolution Failure, and Joint Destruction.Journal of inflammation research · 2026Review
- Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis.Frontiers in immunology · 2026Article
- Exploratory Pilot Study on the Serum Ceramide (16:0) to Sphingosine-1-Phosphate Ratio as a Potential Indicator of Lupus Nephritis and Disease Activity.International journal of molecular sciences · 2025Article
- Lipidomic and transcriptomic profiling reveal alterations in the coexistence of gestational diabetes mellitus and preeclampsia impacting maternal and neonatal outcomes.Scientific reports · 2025Article
- Colocalization analysis reveals shared genetic loci contributing to gout and metabolite levels.Gout, urate, and crystal deposition disease · 2025Article
- Early prediction of bone destruction in rheumatoid arthritis through machine learning analysis of plasma metabolites.Arthritis research & therapy · 2025Article
- Serum phospholipids and sphingolipids are linked to early-stage osteoarthritis by lipidomic profiling.Arthritis research & therapy · 2025Article
- Phospholipids and Sphingolipids in Osteoarthritis.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid mediators are crucial for the pathogenesis of rheumatoid arthritis (RA); however, global analyses have not been undertaken to systematically define the lipidome underlying the dynamics of disease evolution, activation, and resolution. Here, we performed untargeted lipidomics analysis of synovial fluid and serum from RA patients at different disease activities and clinical phases (preclinical phase to active phase to sustained remission). We found that the lipidome profile in RA joint fluid was severely perturbed and that this correlated with the extent of inflammation and severity of synovitis on ultrasonography. The serum lipidome profile of active RA, albeit less prominent than the synovial lipidome, was also distinguishable from that of RA in the sustained remission phase and from that of noninflammatory osteoarthritis. Of note, the serum lipidome profile at the preclinical phase of RA closely mimicked that of active RA. Specifically, alterations in a set of lysophosphatidylcholine, phosphatidylcholine, ether-linked phosphatidylethanolamine, and sphingomyelin subclasses correlated with RA activity, reflecting treatment responses to anti-rheumatic drugs when monitored serially. Collectively, these results suggest that analysis of lipidome profiles is useful for identifying biomarker candidates that predict the evolution of preclinical to definitive RA and could facilitate the assessment of disease activity and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.